

Christopher D Byrne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/632922/publications.pdf>

Version: 2024-02-01

322
papers

20,479
citations

9264

74
h-index

13379

130
g-index

330
all docs

330
docs citations

330
times ranked

19821
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. <i>Gut</i> , 2022, 71, 156-162.	12.1	162
2	A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 212-226.	1.5	4
3	Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. <i>Gut</i> , 2022, 71, 778-788.	12.1	132
4	Weight Change and the Development of Nonalcoholic Fatty Liver Disease in Metabolically Healthy Overweight Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e583-e599.	4.4	9
5	Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>British Journal of Nutrition</i> , 2022, 127, 1613-1620.	2.3	8
6	Interaction of <i>SAMM50</i> -rs738491, <i>PARVB</i> -rs5764455 and <i>PNPLA3</i> -rs738409 Increases Susceptibility to Nonalcoholic Steatohepatitis. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 219-229.	1.4	3
7	Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 28-43.	4.4	40
8	Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed. <i>Gut</i> , 2022, 71, 1695-1696.	12.1	11
9	A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis. <i>Liver International</i> , 2022, 42, 80-91.	3.9	6
10	<i>PNPLA3</i> rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 439-448.	1.4	1
11	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
12	Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function. <i>Proceedings of the Nutrition Society</i> , 2022, 81, 146-161.	1.0	17
13	Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 230-237.	1.4	15
14	Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 180-191.	2.8	46
15	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 154958.	3.4	18
16	Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?. <i>Liver International</i> , 2022, 42, 1496-1502.	3.9	25
17	Association of metabolic dysfunction-associated fatty liver disease with kidney disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 259-268.	9.6	72
18	Decrease in Sleep Duration and Poor Sleep Quality over Time Is Associated with an Increased Risk of Incident Non-Alcoholic Fatty Liver Disease. <i>Journal of Personalized Medicine</i> , 2022, 12, 92.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 367-378.	8.1	92
20	Low heart rate variability from 10-s electrocardiograms is associated with development of non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2022, 12, 1062.	3.3	6
21	J-shaped relationship between serum zinc levels and the severity of hepatic necro-inflammation in patients with MAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1259-1265.	2.6	6
22	Serum 25-hydroxy vitamin D and the risk of low muscle mass in young and middle-aged Korean adults. <i>European Journal of Endocrinology</i> , 2022, 186, 477-487.	3.7	4
23	Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 725-738.	8.9	10
24	Glycemic control predicts the risk of hepatic fibrosis in biopsy-proven NAFLD: a possible mediating role for leukemia inhibitory factor?. , 2022, 1, 30-34.		2
25	Liver fat in adult survivors of severe acute malnutrition. <i>Scientific Reports</i> , 2022, 12, 3690.	3.3	2
26	The effect of wasting and stunting during severe acute malnutrition in infancy on insulin sensitivity and insulin clearance in adult life. <i>Journal of Developmental Origins of Health and Disease</i> , 2022, , 1-7.	1.4	3
27	Long or Irregular Menstrual Cycles and Risk of Prevalent and Incident Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2309-e2317.	3.6	6
28	Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2022, 9, 864570.	2.6	5
29	Why are there no strategies for NAFLD?. <i>Journal of Hepatology</i> , 2022, 76, 763-764.	3.7	3
30	Fasting ketonuria is inversely associated with coronary artery calcification in non-diabetic individuals. <i>Atherosclerosis</i> , 2022, 348, 1-7.	0.8	1
31	Resolution of, and Risk of Incident Non-alcoholic Fatty Liver Disease With Changes in Serum 25-hydroxy Vitamin D Status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3437-e3447.	3.6	7
32	NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status. <i>Hepatology</i> , 2022, 76, 1755-1765.	7.3	13
33	Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex. <i>Hepatology Communications</i> , 2022, 6, 2238-2252.	4.3	11
34	Hepatocellular cystathionine β lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor. <i>Hepatology</i> , 2022, 76, 1794-1810.	7.3	24
35	Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 391-401.	4.7	9
36	How should endocrinologists diagnose and treat non-alcoholic fatty liver disease?. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 478-480.	11.4	0

#	ARTICLE	IF	CITATIONS
37	Lower serum copper concentrations are associated with higher prevalence of nonalcoholic steatohepatitis: a matched case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 838-843.	1.6	3
38	Prediabetes diagnosis is associated with the progression of coronary artery calcification: The Kangbuk Samsung Health Study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2118-2126.	4.4	5
39	Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives. , 2022, 1, 57-65.		7
40	Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. <i>Nature Reviews Endocrinology</i> , 2022, 18, 638-650.	9.6	18
41	Machine learning algorithms based on proteomic data mining accurately predicting the recurrence of hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 2145-2153.	2.8	7
42	Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male. <i>Hepatology International</i> , 2022, 16, 1085-1093.	4.2	6
43	Banting memorial lecture 2022: "Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime". <i>Diabetic Medicine</i> , 2022, 39, .	2.3	9
44	<i>FNDC5</i> polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. <i>British Journal of Nutrition</i> , 2021, 126, 813-824.	2.3	11
45	Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease. <i>Diabetes and Metabolism</i> , 2021, 47, 101152.	2.9	28
46	Non-alcoholic fatty liver disease and childhood obesity. <i>Archives of Disease in Childhood</i> , 2021, 106, 3-8.	1.9	57
47	Extrapulmonary complications of COVID-19: A multisystem disease?. <i>Journal of Medical Virology</i> , 2021, 93, 323-335.	5.0	131
48	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 24-39.	17.8	174
49	Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 552-560.	2.6	7
50	MAFLD and risk of CKD. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154433.	3.4	178
51	A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 345-352.	3.0	41
52	Non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 9-10.	8.1	6
53	NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. <i>Diabetes and Metabolism</i> , 2021, 47, 101215.	2.9	84
54	Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. <i>Gut</i> , 2021, 70, 962-969.	12.1	238

#	ARTICLE	IF	CITATIONS
55	Depression and increased risk of non-alcoholic fatty liver disease in individuals with obesity. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e23.	3.9	30
56	Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	5
57	<scp>Nonalcoholic fatty liver disease</scp> as a metabolic disease in humans: A literature review. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1069-1083.	4.4	104
58	Experiences of adolescents living with Silver-Russell syndrome. <i>Archives of Disease in Childhood</i> , 2021, 106, 1195-1201.	1.9	6
59	Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. <i>Frontiers in Endocrinology</i> , 2021, 12, 604100.	3.5	25
60	Telomerase: a key player in the pathogenesis of non-alcoholic fatty liver disease?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 811-819.	3.0	3
61	Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00321.	2.5	6
62	Update on cardiovascular risk in nonalcoholic fatty liver disease. <i>Current Opinion in Cardiology</i> , 2021, 36, 478-486.	1.8	5
63	TA allele of rs2070673 in the <i>CYP2E1</i> gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2925-2934.	2.8	6
64	Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 593-603.	2.6	19
65	The complex link between NAFLD and type 2 diabetes mellitus – mechanisms and treatments. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 599-612.	17.8	346
66	Fasting Ketonuria and the Risk of Incident Nonalcoholic Fatty Liver Disease With and Without Liver Fibrosis in Nondiabetic Adults. <i>American Journal of Gastroenterology</i> , 2021, 116, 2270-2278.	0.4	5
67	Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , 2021, 74, 474-482.	7.3	102
68	The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1822-1831.	2.6	8
69	Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 578-588.	8.1	206
70	Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes – The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 3464-3473.	2.6	14
71	Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 743-753.	8.1	60
72	Fatty liver disease and changes in dense breasts in pre- and postmenopausal women: the Kangbuk Samsung Health Study. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 343-353.	2.5	0

#	ARTICLE	IF	CITATIONS
73	Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 903-913.	8.1	227
74	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. <i>EClinicalMedicine</i> , 2021, 41, 101145.	7.1	14
75	The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 22-43.	8.9	46
76	Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 430-435.	1.6	12
77	Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study. <i>International Journal of Medical Sciences</i> , 2021, 18, 3624-3630.	2.5	4
78	Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD. <i>Nutrition and Diabetes</i> , 2021, 11, 32.	3.2	13
79	Transient elastography in patients at risk of liver fibrosis in primary care: a follow-up study over 54 months. <i>BJGP Open</i> , 2021, , BJGPO.2021.0145.	1.8	4
80	Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00417.	2.5	1
81	Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00417.	2.5	13
82	Multi-drug approaches to NASH: whatâ€™s in the development pipeline?. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 143-150.	4.1	18
83	Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography. <i>Diabetes and Metabolism</i> , 2020, 46, 150-157.	2.9	29
84	Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis. <i>Hepatology</i> , 2020, 71, 861-873.	7.3	49
85	In vitro effects of Bifidobacterium lactis-based synbiotics on human faecal bacteria. <i>Food Research International</i> , 2020, 128, 108776.	6.2	13
86	Effect of <i>PNPLA3</i> polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1057-1064.	2.8	27
87	<i>PNPLA3</i> rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. <i>Liver International</i> , 2020, 40, 107-119.	3.9	67
88	Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. <i>Diabetes and Metabolism</i> , 2020, 46, 427-441.	2.9	81
89	Whatâ€™s new in NAFLD pathogenesis, biomarkers and treatment?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 70-71.	17.8	40
90	Treatment algorithm in patients with type 2 diabetes and atherosclerotic cardiovascular disease or high/very high cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 331-331.	2.2	5

#	ARTICLE	IF	CITATIONS
91	Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD. <i>Diabetes and Metabolism</i> , 2020, 46, 288-295.	2.9	24
92	Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 296-303.	2.9	47
93	Non-invasive fibrosis assessment in non-alcoholic fatty liver disease. <i>Chinese Medical Journal</i> , 2020, 133, 2743-2745.	2.3	7
94	Factors independently associated with cardiorespiratory fitness in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2998-3007.	3.9	5
95	Disabling MNK protein kinases promotes oxidative metabolism and protects against diet-induced obesity. <i>Molecular Metabolism</i> , 2020, 42, 101054.	6.5	18
96	Abnormal liver enzymes in children and infants with COVID-19: A narrative review of case-series studies. <i>Pediatric Obesity</i> , 2020, 15, e12723.	2.8	18
97	ACE2: A Linkage for the Interplay Between COVID-19 and Decompensated Cirrhosis. <i>American Journal of Gastroenterology</i> , 2020, 115, 1544-1544.	0.4	14
98	Diabetes is associated with increased risk of hepatocellular carcinoma in non-alcoholic steatohepatitis with cirrhosis—implications for surveillance and future pharmacotherapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 230-234.	1.5	2
99	Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. <i>Gut</i> , 2020, 69, 1545-1547.	12.1	166
100	Patients with diabetes are at higher risk for severe illness from COVID-19. <i>Diabetes and Metabolism</i> , 2020, 46, 335-337.	2.9	124
101	Obesity Is a Risk Factor for Greater COVID-19 Severity. <i>Diabetes Care</i> , 2020, 43, e72-e74.	8.6	323
102	Subclinical Acute Kidney Injury in COVID-19 Patients: A Retrospective Cohort Study. <i>Nephron</i> , 2020, 144, 347-350.	1.8	21
103	Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis. <i>Frontiers in Physiology</i> , 2020, 11, 551.	2.8	5
104	Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1236-1248.	2.6	196
105	Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. <i>Diabetes and Metabolism</i> , 2020, 46, 505-507.	2.9	34
106	PNPLA3 gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. <i>Liver International</i> , 2020, 40, 1130-1141.	3.9	33
107	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. <i>Gerontology</i> , 2020, 66, 447-459.	2.8	4
108	Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2041-2050.	2.8	67

#	ARTICLE	IF	CITATIONS
109	Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1820-1825.	2.6	9
110	Noninvasive liver fibrosis scores are strongly associated with liver cancer mortality in general population without liver disease. <i>Liver International</i> , 2020, 40, 1303-1315.	3.9	9
111	PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. <i>Diabetes and Metabolism</i> , 2020, 46, 496-503.	2.9	5
112	Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1597-1610.e7.	1.3	123
113	Complications, morbidity and mortality of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154170.	3.4	278
114	Development and validation of a novel noninvasive test for diagnosing fibrotic nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1804-1812.	2.8	15
115	NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. <i>Gut</i> , 2020, 69, 1691-1705.	12.1	369
116	NAFLD as a driver of chronic kidney disease. <i>Journal of Hepatology</i> , 2020, 72, 785-801.	3.7	249
117	COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-7.	1.4	329
118	Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD). <i>Current Pharmaceutical Design</i> , 2020, 26, 1079-1092.	1.9	31
119	An Experimental Series Investigating the Effects of Hyperinsulinemic Euglycemia on Myocardial Blood Flow Reserve in Healthy Individuals and on Myocardial Perfusion Defect Size following ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 868-877.e6.	2.8	0
120	NAFLD and Cardiovascular and Cardiac Disease: Clinical Implications. , 2020, , 169-197.		0
121	Lived experience of Silver-Russell syndrome: implications for management during childhood and into adulthood. <i>Archives of Disease in Childhood</i> , 2019, 104, 76-82.	1.9	13
122	Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 2317-2329.	3.9	24
123	Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 802-810.	3.7	39
124	Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. <i>Digestive and Liver Disease</i> , 2019, 51, 1586-1592.	0.9	34
125	Maternal Obesity during Pregnancy Alters Daily Activity and Feeding Cycles, and Hypothalamic Clock Gene Expression in Adult Male Mouse Offspring. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5408.	4.1	11
126	Low Levels of Low-Density Lipoprotein Cholesterol and Mortality Outcomes in Non-Statins Users. <i>Journal of Clinical Medicine</i> , 2019, 8, 1571.	2.4	30

#	ARTICLE	IF	CITATIONS
127	Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis. <i>Hepatology</i> , 2019, 70, 812-823.	7.3	30
128	Decreased lung function is associated with risk of developing non-alcoholic fatty liver disease: A longitudinal cohort study. <i>PLoS ONE</i> , 2019, 14, e0208736.	2.5	23
129	Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. <i>Liver International</i> , 2019, 39, 758-769.	3.9	75
130	Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis. <i>Diabetes and Metabolism</i> , 2019, 45, 536-544.	2.9	25
131	Cardiovascular Health Metrics in the Development and Regression of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 610.	2.4	9
132	Diagnosis and management of non-alcoholic fatty liver disease. <i>Postgraduate Medical Journal</i> , 2019, 95, 314-322.	1.8	70
133	Association between <i>Helicobacter pylori</i> infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 56-65.	3.4	38
134	Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. <i>Hepatology</i> , 2019, 70, 142-153.	7.3	44
135	The evaluation of the repeatability of the ¹³ C-ketoisocaproate breath test for assessing hepatic mitochondrial function. <i>Isotopes in Environmental and Health Studies</i> , 2019, 55, 150-160.	1.0	0
136	Letter: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 961-962.	3.7	0
137	Non alcoholic fatty liver disease and risk of incident diabetes in subjects who are not obese. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 489-495.	2.6	24
138	Multi-domain analysis of microvascular flow motion dynamics in NAFLD. <i>Microcirculation</i> , 2019, 26, e12538.	1.8	9
139	Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. <i>Diabetes and Metabolism</i> , 2019, 45, 480-487.	2.9	36
140	Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: Plasma proteomics in the randomized WELCOME* trial. <i>Clinical Nutrition</i> , 2019, 38, 1952-1955.	5.0	7
141	Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 375-388.	3.7	45
142	Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. <i>Gut</i> , 2019, 68, 1667-1675.	12.1	130
143	Does high LDL-cholesterol cause cardiovascular disease?. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 91-91.	3.1	2
144	Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2019, 45, 347-355.	2.9	47

#	ARTICLE	IF	CITATIONS
145	Nonalcoholic Fatty Liver Disease in Children. <i>Seminars in Liver Disease</i> , 2018, 38, 001-013.	3.6	108
146	Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis severity in NAFLD. <i>Journal of Leukocyte Biology</i> , 2018, 104, 631-639.	3.3	25
147	Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. <i>Diabetes Care</i> , 2018, 41, 372-382.	8.6	407
148	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2018, 14, 99-114.	9.6	284
149	Liver fat content, non-alcoholic fatty liver disease, and risk of ischaemic heart disease. <i>European Heart Journal</i> , 2018, 39, 3398-3398.	2.2	3
150	Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. <i>Molecular Aspects of Medicine</i> , 2018, 64, 135-146.	6.4	103
151	Resolution of fatty liver and weight loss: Independent associations with changes in serum lipids and apolipoproteins. <i>Atherosclerosis</i> , 2018, 272, 47-53.	0.8	10
152	Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with <sc>NAFLD</sc>. <i>Liver International</i> , 2018, 38, 342-349.	3.9	37
153	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. <i>Diabetes Care</i> , 2018, 41, 341-347.	8.6	92
154	Reply to: "Energy drinks and adolescents" A hepatic health hazard? <i>Journal of Hepatology</i> , 2018, 68, 857-858.	3.7	0
155	Liver zonation in children with non-alcoholic fatty liver disease: Associations with dietary fructose and uric acid concentrations. <i>Liver International</i> , 2018, 38, 1102-1109.	3.9	20
156	Non-alcoholic fatty liver disease: A risk factor for myocardial dysfunction?. <i>Journal of Hepatology</i> , 2018, 68, 640-642.	3.7	7
157	Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2018, 79, 64-76.	3.4	261
158	Association of Plasma Ceramides With Myocardial Perfusion in Patients With Coronary Artery Disease Undergoing Stress Myocardial Perfusion Scintigraphy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2854-2861.	2.4	29
159	Relationship between non-alcoholic steatohepatitis, PNPLA3 I148M genotype and bone mineral density in adolescents. <i>Liver International</i> , 2018, 38, 2301-2308.	3.9	12
160	Association between decreasing estimated glomerular filtration rate and risk of cardiac conduction defects in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2018, 44, 473-481.	2.9	2
161	Obesity and incidence of diabetes: Effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver. <i>Atherosclerosis</i> , 2018, 275, 50-57.	0.8	40
162	Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy. <i>Metabolism: Clinical and Experimental</i> , 2018, 85, 305-312.	3.4	15

#	ARTICLE	IF	CITATIONS
163	Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2018, 71, 113-123.	1.8	31
164	The characterisation of hepatic mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD) using the ¹³ C-ketoisocaproate breath test. <i>Journal of Breath Research</i> , 2018, 12, 046002.	3.0	23
165	Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2018, 87, 1-12.	3.4	80
166	Nutritional Targeting of Cancer Cell Metabolism in Obesity. <i>Journal of Nutrition</i> , 2018, 148, 1207-1208.	2.9	0
167	Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. <i>BMJ: British Medical Journal</i> , 2018, 362, k2734.	2.3	81
168	Ad Libitum Mediterranean or Low-Fat Diets as Treatments for Nonalcoholic Fatty Liver Disease?. <i>Hepatology</i> , 2018, 68, 1668-1671.	7.3	6
169	Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2017, 13, 297-310.	9.6	219
170	Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. <i>Journal of Hepatology</i> , 2017, 66, 1031-1036.	3.7	128
171	Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop. <i>Journal of Nutritional Science</i> , 2017, 6, e15.	1.9	10
172	Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study. <i>European Journal of Clinical Nutrition</i> , 2017, 71, 973-979.	2.9	51
173	Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis. <i>Current Diabetes Reports</i> , 2017, 17, 20.	4.2	26
174	Myocardial blood flow reserve is impaired in patients with aortic valve calcification and unobstructed epicardial coronary arteries. <i>International Journal of Cardiology</i> , 2017, 248, 427-432.	1.7	3
175	Reply to: Fructose, uric acid and zonal differences in NASH. <i>Journal of Hepatology</i> , 2017, 67, 1118-1119.	3.7	1
176	Baseline and Change in Uric Acid Concentration Over Time Are Associated With Incident Hypertension in Large Korean Cohort. <i>American Journal of Hypertension</i> , 2017, 30, 42-50.	2.0	27
177	Randomised controlled trial and economic analysis of an internet-based weight management programme: POWeR+ (Positive Online Weight Reduction). <i>Health Technology Assessment</i> , 2017, 21, 1-62.	2.8	36
178	Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. <i>International Journal of Molecular Sciences</i> , 2016, 17, 367.	4.1	96
179	Nonalcoholic fatty liver disease, cardiovascular outcomes, and mortality in patients undergoing a coronary angiogram. <i>Hepatology</i> , 2016, 64, 684-685.	7.3	4
180	Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology</i> , 2016, 64, 1388-1389.	7.3	104

#	ARTICLE	IF	CITATIONS
181	Glycaemic control and lipid concentrations in a cohort of people with diabetes over 7 years of follow-up: a regional audit of diabetes care in the UK. <i>Diabetic Medicine</i> , 2016, 33, 386-390.	2.3	1
182	Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. <i>Journal of Hepatology</i> , 2016, 65, 589-600.	3.7	965
183	EASL/EASD/EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?. <i>Diabetologia</i> , 2016, 59, 1141-1144.	6.3	78
184	Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?. <i>Diabetes and Metabolism</i> , 2016, 42, 142-156.	2.9	78
185	Body mass index and mortality: understanding the patterns and paradoxes. <i>BMJ, The</i> , 2016, 353, i2433.	6.0	16
186	All cause mortality and body mass index in a young Asian occupational cohort without baseline metabolic syndrome components. <i>International Journal of Cardiology</i> , 2016, 224, 271-278.	1.7	9
187	Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis. <i>Digestive Diseases</i> , 2016, 34, 11-18.	1.9	33
188	Insulin in Acute Coronary Syndrome: a Narrative Review with Contemporary Perspectives. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 493-504.	2.6	5
189	Urine Albumin/Creatinine Ratio Below 30 mg/g is a Predictor of Incident Hypertension and Cardiovascular Mortality. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	65
190	MNK1 and MNK2 mediate adverse effects of high-fat feeding in distinct ways. <i>Scientific Reports</i> , 2016, 6, 23476.	3.3	29
191	Insulin-induced hypoglycaemia and the detection of myocardial injury using an ultrasensitive troponin assay. <i>International Journal of Cardiology</i> , 2016, 215, 446-448.	1.7	0
192	Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial. <i>Diabetologia</i> , 2016, 59, 1422-1429.	6.3	6
193	Altered cellular redox status, sirtuin abundance and clock gene expression in a mouse model of developmentally primed NASH. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 584-593.	2.4	24
194	Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. <i>Journal of Hepatology</i> , 2016, 65, 791-797.	3.7	102
195	Metabolically healthy obesity and NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 442-444.	17.8	55
196	Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. <i>Journal of Hepatology</i> , 2016, 64, 1358-1364.	3.7	67
197	Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. <i>Atherosclerosis</i> , 2016, 246, 13-20.	0.8	54
198	Fatty Liver, Insulin Resistance, and Obesity: Relationships With Increase in Coronary Artery Calcium Over Time. <i>Clinical Cardiology</i> , 2016, 39, 321-328.	1.8	20

#	ARTICLE	IF	CITATIONS
199	Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure. <i>Medicine (United States)</i> , 2016, 95, e2760.	1.0	17
200	Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 7-10.	1.3	36
201	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 106-120.	6.1	37
202	Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. <i>PLoS ONE</i> , 2016, 11, e0168216.	2.5	83
203	Gallstone Disease and Increased Risk of Ischemic Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2073-2075.	2.4	10
204	Mulberry extract to modulate Blood glucose Responses in normoglycaemic adults (MULBERRY): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 486.	1.6	10
205	Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study. <i>Clinical Hypertension</i> , 2015, 21, 22.	2.0	4
206	Increased Cardiovascular Mortality in Subjects With Metabolic Syndrome Is Largely Attributable to Diabetes and Hypertension in 159 971 Korean Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2606-2612.	3.6	21
207	Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 879-887.	3.4	82
208	A Bayesian network for modelling blood glucose concentration and exercise in type 1 diabetes. <i>Statistical Methods in Medical Research</i> , 2015, 24, 342-372.	1.5	11
209	An increased high-density lipoprotein cholesterol/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality. <i>Heart</i> , 2015, 101, 553-558.	2.9	27
210	Î³-Glutamyl Transferase Is Associated with Mortality Outcomes Independently of Fatty Liver. <i>Clinical Chemistry</i> , 2015, 61, 1173-1181.	3.2	20
211	All-Cause and Cardiovascular Mortality Among Koreans. <i>American Journal of Preventive Medicine</i> , 2015, 49, 62-71.	3.0	41
212	Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial. <i>Diabetologia</i> , 2015, 58, 1916-1925.	6.3	18
213	NAFLD: A multisystem disease. <i>Journal of Hepatology</i> , 2015, 62, S47-S64.	3.7	2,037
214	Circulating Markers of Liver Function and Cardiovascular Disease Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2290-2296.	2.4	54
215	A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. <i>Metabolic Syndrome and Related Disorders</i> , 2015, 13, 235-238.	1.3	27
216	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. <i>Digestive and Liver Disease</i> , 2015, 47, 997-1006.	0.9	368

#	ARTICLE	IF	CITATIONS
217	Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. <i>Journal of Hepatology</i> , 2015, 63, 1476-1483.	3.7	90
218	Views of People With High and Low Levels of Health Literacy About a Digital Intervention to Promote Physical Activity for Diabetes: A Qualitative Study in Five Countries. <i>Journal of Medical Internet Research</i> , 2015, 17, e230.	4.3	93
219	Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study. <i>Hepatology</i> , 2014, 60, 1211-1221.	7.3	263
220	Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 663-669.	2.6	77
221	Nonalcoholic Fatty Liver Disease Is Independently Associated With an Increased Incidence of Chronic Kidney Disease in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2014, 37, 1729-1736.	8.6	129
222	The reduced cost of providing a nationally recognised service for familial hypercholesterolaemia. <i>Open Heart</i> , 2014, 1, e000015.	2.3	12
223	High-sensitivity C-reactive Protein Is Associated with the Presence of Coronary Artery Calcium in Subjects with Normal Blood Pressure but Not in Subjects with Hypertension. <i>Archives of Medical Research</i> , 2014, 45, 170-176.	3.3	12
224	CKD and Nonalcoholic Fatty Liver Disease. <i>American Journal of Kidney Diseases</i> , 2014, 64, 638-652.	1.9	163
225	Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. <i>Journal of Hepatology</i> , 2014, 60, 1040-1045.	3.7	124
226	Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2014, 37, 301-311.	1.8	42
227	Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1155-1161.	2.4	124
228	Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 256-262.	2.6	54
229	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 1724.	3.3	207
230	C-reactive protein and risk of cardiovascular and all-cause mortality in 268 803 East Asians. <i>European Heart Journal</i> , 2014, 35, 1809-1816.	2.2	46
231	Daily Energy Expenditure, Cardiorespiratory Fitness and Glycaemic Control in People with Type 1 Diabetes. <i>PLoS ONE</i> , 2014, 9, e97534.	2.5	7
232	Evaluation of Bioelectrical Impedance Analysis for Identifying Overweight Individuals at Increased Cardiometabolic Risk: A Cross-Sectional Study. <i>PLoS ONE</i> , 2014, 9, e106134.	2.5	11
233	Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. <i>Proceedings of the Nutrition Society</i> , 2013, 72, 412-419.	1.0	77
234	Late effects of childhood cancer treatment: severe hypertriglyceridaemia, central obesity, non alcoholic fatty liver disease and diabetes as complications of childhood total body irradiation. <i>Diabetic Medicine</i> , 2013, 30, e239-42.	2.3	31

#	ARTICLE	IF	CITATIONS
235	Towards a personalised diagnosis of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 6-7.	11.4	0
236	Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 483-495.	3.6	259
237	Nonalcoholic Fatty Liver Disease and Reduced Serum Vitamin D ³ Levels. <i>Metabolic Syndrome and Related Disorders</i> , 2013, 11, 217-228.	1.3	29
238	Resolution of Fatty Liver and Risk of Incident Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3637-3643.	3.6	143
239	Diagnosis and Management of Nonalcoholic Fatty Liver Disease and Its Hemostatic/Thrombotic and Vascular Complications. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 214-228.	2.7	56
240	Non-Alcoholic Fatty Liver Disease Is Associated with an Increased Incidence of Atrial Fibrillation in Patients with Type 2 Diabetes. <i>PLoS ONE</i> , 2013, 8, e57183.	2.5	153
241	Fatty Liver, Insulin Resistance, and Features of Metabolic Syndrome. <i>Diabetes Care</i> , 2012, 35, 2359-2364.	8.6	125
242	Combined Influence of Insulin Resistance, Overweight/Obesity, and Fatty Liver as Risk Factors for Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 717-722.	8.6	176
243	<i>Dorothy Hodgkin Lecture 2012</i> Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. <i>Diabetic Medicine</i> , 2012, 29, 1098-1107.	2.3	81
244	Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. <i>European Heart Journal</i> , 2012, 33, 1190-1200.	2.2	372
245	Predicting incident fatty liver using simple cardio-metabolic risk factors at baseline. <i>BMC Gastroenterology</i> , 2012, 12, 84.	2.0	30
246	Functional Dilator Capacity is Independently Associated with Insulin Sensitivity and Age in Central Obesity and is not Improved by High Dose Statin Treatment. <i>Microcirculation</i> , 2011, 18, 74-84.	1.8	21
247	A single enteral feed prior to the commencement of parenteral nutrition ameliorates the incidence of steatosis in parenterally fed neonatal piglets. <i>Metabolomics</i> , 2011, 7, 118-125.	3.0	0
248	Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. <i>Endocrine</i> , 2011, 40, 332-343.	2.3	57
249	Hypoxia and non-alcoholic fatty liver disease. <i>Clinical Science</i> , 2010, 118, 397-400.	4.3	30
250	Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?. <i>Drug Discovery Today</i> , 2010, 15, 590-595.	6.4	13
251	Potential therapeutic uses for ezetimibe beyond lowering LDL to decrease cardiovascular events. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 958-966.	4.4	16
252	Diastolic function is strongly and independently associated with cardiorespiratory fitness in central obesity. <i>Journal of Applied Physiology</i> , 2010, 108, 1568-1574.	2.5	11

#	ARTICLE	IF	CITATIONS
253	Non-Alcoholic Fatty Liver Disease (NAFLD): New challenge for general practitioners and important burden for health authorities?. Primary Care Diabetes, 2010, 4, 129-137.	1.8	56
254	Fatty liver: Role of inflammation and fatty acid nutrition. Prostaglandins Leukotrienes and Essential Fatty Acids, 2010, 82, 265-271.	2.2	93
255	Muscle Microvascular Dysfunction in Central Obesity Is Related to Muscle Insulin Insensitivity but Is Not Reversed by High-Dose Statin Treatment. Diabetes, 2009, 58, 1185-1191.	0.6	24
256	The metabolic syndrome: common origins of a multifactorial disorder. Postgraduate Medical Journal, 2009, 85, 614-621.	1.8	123
257	Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. Hepatology, 2009, 50, 1796-1808.	7.3	391
258	Current treatment of non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism, 2009, 11, 188-195.	4.4	70
259	Skeletal muscle microvascular exchange capacity is associated with hyperglycaemia in subjects with central obesity. Diabetic Medicine, 2009, 26, 1112-1119.	2.3	10
260	Metabolic disturbances in non-alcoholic fatty liver disease. Clinical Science, 2009, 116, 539-564.	4.3	210
261	Decreased microvascular functional vasodilatory reserve and features of the metabolic syndrome. FASEB Journal, 2008, 22, 1141-1148.	0.5	0
262	Treating non-alcoholic fatty liver disease. Practice Nursing, 2007, 18, 120-126.	0.1	1
263	Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discovery Today, 2007, 12, 740-747.	6.4	158
264	Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men. Diabetologia, 2007, 50, 1024-1032.	6.3	44
265	Insulin resistance and cortisol metabolism. Reply to Kerstens MN, Dullaart RPF [letter]. Diabetologia, 2007, 50, 2025-2026.	6.3	0
266	Non-alcoholic Steatohepatitis. , 2006, , 279-303.		17
267	Growth Hormone, Exercise and Energy Expenditure in the Metabolic Syndrome. , 2006, , 353-380.		0
268	Oxidative Stress, Insulin Resistance and Cardiovascular Disease. , 2006, , 189-205.		1
269	Inflammation, Cardiovascular Disease and the Metabolic Syndrome. , 2006, , 207-238.		0
270	Treatments for the Metabolic Syndrome. , 2006, , 381-406.		1

#	ARTICLE	IF	CITATIONS
271	Developmental Origins of Insulin Resistance and Type 2 Diabetes. , 2006, , 123-142.		0
272	Recent Progress in the Identification of Genes Predisposing to the Metabolic Syndrome. , 2006, , 143-162.		0
273	Adipocytokines and the Pathogenesis of the Metabolic Syndrome. , 2006, , 239-262.		1
274	Developmental Origins of Vascular Dysfunction and Disease. , 2006, , 85-122.		0
275	Ethnicity and the Metabolic Syndrome. , 2006, , 43-84.		4
276	Differences in cortisol concentrations in South Asian and European men living in the United Kingdom. Clinical Endocrinology, 2006, 64, 530-534.	2.4	20
277	Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia, 2006, 49, 49-55.	6.3	94
278	Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia, 2006, 49, 141-148.	6.3	88
279	The Global Burden of the Metabolic Syndrome and its Consequences for Diabetes and Cardiovascular Disease. , 2006, , 1-41.		26
280	Effects of VLDL and Remnant Particles on Platelets. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 281-291.	0.3	79
281	Nutrition: It's Relevance in Development and Treatment of the Metabolic Syndrome. , 2006, , 333-352.		0
282	Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes. ACP Journal Club, 2005, 142, 18.	0.1	0
283	Review: Fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes. ACP Journal Club, 2005, 142, 18.	0.1	0
284	Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2004, 6, 308-309.	4.4	1
285	Evidence for fetal programming of obesity with a focus on putative mechanisms. Nutrition Research Reviews, 2004, 17, 153-162.	4.1	21
286	Identification and Functional Characterization of a Novel 27bp Deletion in the Macroglycopeptide-Coding Region of the GPIIb/IIIa Gene Resulting in Platelet-Type Von Willebrand Disease.. Blood, 2004, 104, 1023-1023.	1.4	2
287	A Novel Role for CD36 in VLDL-Enhanced Platelet Activation. Diabetes, 2003, 52, 1248-1255.	0.6	52
288	Increased Glucocorticoid Receptor Expression in Human Skeletal Muscle Cells May Contribute to the Pathogenesis of the Metabolic Syndrome. Diabetes, 2002, 51, 1066-1075.	0.6	167

#	ARTICLE	IF	CITATIONS
289	Effects of maternal iron restriction in the rat on hypoxia-induced gene expression and fetal metabolite levels. <i>British Journal of Nutrition</i> , 2001, 85, 193-201.	2.3	117
290	Adipocyte metabolism and the metabolic syndrome. <i>Diabetes, Obesity and Metabolism</i> , 2001, 3, 129-142.	4.4	25
291	Does tumour necrosis factor $\hat{\pm}$ influence insulin sensitivity in skeletal muscle?. <i>Clinical Science</i> , 2000, 99, 329-330.	4.3	4
292	Differential hepatic lobar gene expression in offspring exposed to altered maternal dietary protein intake. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, G128-G136.	3.4	29
293	Fetal origins of adult disease: epidemiology and mechanisms. <i>Journal of Clinical Pathology</i> , 2000, 53, 822-828.	2.0	81
294	Does tumour necrosis factor alpha influence insulin sensitivity in skeletal muscle?. <i>Clinical Science</i> , 2000, 99, 329-30.	4.3	0
295	Fasting proinsulin concentrations predict the development of type 2 diabetes. <i>Diabetes Care</i> , 1999, 22, 262-270.	8.6	158
296	Cross-sectional but not longitudinal associations between non-esterified fatty acid levels and glucose intolerance and other features of the metabolic syndrome. <i>Diabetic Medicine</i> , 1999, 16, 1007-1015.	2.3	31
297	Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype?. <i>Atherosclerosis</i> , 1999, 145, 1-15.	0.8	34
298	Differential priming of RNA templates during cDNA synthesis markedly affects both accuracy and reproducibility of quantitative competitive reverse-transcriptase PCR. <i>Biochemical Journal</i> , 1999, 337, 231-241.	3.7	78
299	Differential priming of RNA templates during cDNA synthesis markedly affects both accuracy and reproducibility of quantitative competitive reverse-transcriptase PCR. <i>Biochemical Journal</i> , 1999, 337, 231.	3.7	36
300	Activated Protein C Resistance: Effect of Platelet Activation, Platelet-Derived Microparticles, and Atherogenic Lipoproteins. <i>Blood</i> , 1999, 93, 3792-3797.	1.4	2
301	Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF- $\hat{1}^2$ levels. <i>Atherosclerosis</i> , 1998, 140, 45-53.	0.8	57
302	A quantitative analysis of the relationship between habitual energy expenditure, fitness and the metabolic cardiovascular syndrome. <i>British Journal of Nutrition</i> , 1998, 80, 235-241.	2.3	84
303	Atherogenic Lipoproteins Support Assembly of the Prothrombinase Complex and Thrombin Generation: Modulation by Oxidation and Vitamin E. <i>Blood</i> , 1998, 91, 508-515.	1.4	99
304	The role of insulin and proinsulin in the regulation of triglyceride metabolism. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1997, 105, 29-35.	1.2	1
305	Two variants of quantitative reverse transcriptase PCR used to show differential expression of $\hat{1}^{\pm}$, $\hat{1}^2$ - and $\hat{1}^3$ -fibrinogen genes in rat liver lobes. <i>Biochemical Journal</i> , 1997, 321, 769-776.	3.7	57
306	A novel highly reproducible quantitative competitive RT PCR system. <i>Journal of Molecular Biology</i> , 1997, 274, 338-352.	4.2	23

#	ARTICLE	IF	CITATIONS
307	Thrombin Generation by Apoptotic Vascular Smooth Muscle Cells. <i>Blood</i> , 1997, 89, 4378-4384.	1.4	140
308	Pathological bone fractures preceded by sustained hypercalcaemia in type 1 Gaucher disease. <i>Journal of Inherited Metabolic Disease</i> , 1997, 20, 709-710.	3.6	6
309	Is an exaggerated postprandial triglyceride response associated with the component features of the insulin resistance syndrome?. , 1997, 14, 942-950.		10
310	The association between free fatty acid concentrations and triglyceride-rich lipoproteins in the post-prandial state is altered by a common deletion polymorphism of the apo B signal peptide. <i>Atherosclerosis</i> , 1996, 127, 35-42.	0.8	14
311	IS PLATELET PHOSPHOLIPID-DEPENDENT THROMBIN GENERATION ALTERED BY ACUTE MYOCARDIAL INFARCTION OR ASPIRIN?. <i>Thrombosis Research</i> , 1996, 83, 329-338.	1.7	14
312	Decreased non-esterified fatty acid suppression and features of the insulin resistance syndrome occur in a sub-group of individuals with normal glucose tolerance. <i>Diabetologia</i> , 1995, 38, 1358-1366.	6.3	34
313	The 30 Minute Insulin Incremental Response in an Oral Glucose Tolerance Test as a Measure of Insulin Secretion. <i>Diabetic Medicine</i> , 1995, 12, 931-931.	2.3	161
314	Undiagnosed Glucose Intolerance in the Community: the Isle of Ely Diabetes Project. <i>Diabetic Medicine</i> , 1995, 12, 30-35.	2.3	154
315	Decreased non-esterified fatty acid suppression and features of the insulin resistance syndrome occur in a sub-group of individuals with normal glucose tolerance. <i>Diabetologia</i> , 1995, 38, 1358-1366.	6.3	5
316	Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. <i>Diabetologia</i> , 1994, 37, 889-896.	6.3	80
317	Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. <i>Diabetologia</i> , 1994, 37, 889-896.	6.3	9
318	Control of Hep G2-cell triacylglycerol and apolipoprotein B synthesis and secretion by polyunsaturated non-esterified fatty acids and insulin. <i>Biochemical Journal</i> , 1992, 288, 101-107.	3.7	54
319	Interaction of non-esterified fatty acid and insulin in control of triacylglycerol secretion by Hep G2 cells. <i>Biochemical Journal</i> , 1991, 280, 99-104.	3.7	72
320	PCSK9 inhibition for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia. <i>The Cochrane Library</i> , 0, , .	2.8	0
321	Atherothrombosis and the Metabolic Syndrome. , 0, , 163-187.		1
322	Higher Levels of Plasma Hyaluronic Acid and N-terminal Propeptide of Type III Procollagen Are Associated With Lower Kidney Function in Children With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Pediatrics</i> , 0, 10, .	1.9	1